Focus on increasing throughput of processes has favoured poorer models with lower chances of success
The search for new medicines is becoming unsustainably expensive despite huge technological advances because researchers are using the wrong methods, experts say.
They say drug discovery should focus on ‘validity’ – how well the results of experiments predict results in sick people. Instead, it has focused on methods that are easy to industrialize or methods that are academically fashionable.
In a report published in the journal PLOS ONE, Jack Scannell, from Oxford University’s Centre for the Advancement of Sustainable Medical Innovation, and consultant Jim Bosley approach drug discovery using mathematical tools that are used by economists to study decision making. They show that the chance of discovering an effective drug is surprisingly sensitive to the validity of the experimental methods. Small changes in validity can have a bigger effect than running 10 or even 100 times more experiments.
They argue that productivity has declined because the most predictive methods lead to the discovery of good drugs, and research in those areas stops (e.g., stomach ulcers). This leaves scientists working on as-yet-untreated diseases using less predictive discovery methods (e.g., Alzheimer’s). They also suggest that changing industrial and scientific fashions have contributed to the problem.
The result: Methods have become less predictive over time, worse decisions have been made, and the cost of discovery has gone up.
Drug approvals have increased since 2012. The researchers say that this is likely down to the rising use of genetic information which improves the validity of the methods to discover treatments for rare diseases, though less so for common diseases.
Dr Jack Scannell said: ‘There is a nasty puzzle at the heart of modern biomedical research. On one hand, the technologies that people think are important have become hundreds, thousands, or even billions of times cheaper. On the other hand, it costs nearly 100 times more to bring a drug to market today than it did in 1950. New drugs can be very expensive, yet the industry is closing labs and firing scientists. Our work goes some way towards explaining the puzzle. Governments, companies, and charities should focus on identifying and funding predictive methods, even if they don’t match current scientific fashion.’
The Latest on: Drug development crisis
via Google News
The Latest on: Drug development crisis
- Ensure treatment for all: Government must make coronavirus drug accessibleon July 3, 2020 at 1:58 am
We’re all in this together, or so we are often told when it comes to the coronavirus crisis. If it applies to wearing masks in public and keeping socially distant, it has to apply to a lifesaving ...
- Computer-Aided Drug Design added to global fight against COVID-19on July 2, 2020 at 7:44 am
Cutting edge chemical science technology and computer-aided drug design (CADD) is bringing together leading minds from across the world to help tackle the COVID-19 crisis. Life sciences company UCB is ...
- Europe Says It Has Plenty of Gilead Covid Drug After U.S. Dealon July 1, 2020 at 10:49 am
Countries including Britain, Germany and Switzerland sought to allay concerns that they won’t have sufficient stocks of Gilead Sciences Inc.’s remdesivir, one of two drugs shown to treat Covid-19, ...
- Perspectives: Lack Of Political Courage, Unwillingness To Compromise Hurting America’s Drug-Pricing Systemon June 30, 2020 at 10:49 am
Read recent commentaries about drug-cost issues. The Wall Street Jour ...
- Gilead says it will charge $3,120 per patient for COVID-19 drugon June 29, 2020 at 9:57 am
Gilead will begin charging U.S. patients for the experimental COVID-19 drug remdesivir in two weeks, the company and the government announced Monday, as cases surge and hospitalizations reach crisis ...
- Gilead prices COVID-19 drug remdesivir, faces competitionon June 29, 2020 at 9:20 am
Remdesivir is at the forefront of the fight against COVID-19 after it helped shorten hospital recovery times in a trial.
- Drug Arrests Still Costing NYC Millions As Residents Beg For Aid, Freedom For City Familieson June 28, 2020 at 5:03 pm
A new brief from drug reform advocates reveals that New York City remains a hotbed for low-level drug and 'broken windows' arrests of mostly Black and Brown residents, at enormous expense to all.
- COVID-19 crisis and economic downturn threaten to compound drug dangers further still, warns World Drug Report 2020on June 25, 2020 at 5:00 pm
"The COVID-19 crisis and economic downturn threaten to compound drug dangers further still ... so we can achieve the Sustainable Development Goals, promote justice and leave no one behind," concluded ...
- Virtual clinical trials now being used to fast-track drug development during coronavirus crisison June 25, 2020 at 5:51 am
Eager to streamline the process of drug development during the pandemic, researchers, pharmaceutical companies and a handful of tech start-ups have started virtual clinical trials, also known as ...
- New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meetingon June 12, 2020 at 9:42 am
Now that Pfizer’s development and commercialization rights, including the investigational new drug (IND) application for rivipansel, have been transferred back to us, we intend to discuss these ...
via Bing News